The Kodiak thing has my head spinning. If that happened to PYC as they entered P1 trials it could be the way the valuation change occurs. If they sell 5% (more than Kodiak did) of Visionpharma for USD200m (less than Kodiak got) then the remaining 80% would be instantly valued at USD3.2b and there could be a capital return equal to PYCs current share price (80% of USD200m = AUD230m).
that would be the best way to get the share price revalued and only give away 5% of one subsidiary.
mind blowing numbers.
Ann: Drug Delivery Greater Than 100% More Effective In Animals, page-16
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.21 | $1.13 | $387.7K | 327.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |